Objectives: To evaluate IgPro20 (SCIG) as a maintenance treatment in CIDP.
Methods: A randomized, double-blind trial in CIDP patients (n5172) investigated 0.2 and 0.4 g/kg weekly doses of IgPro20 versus placebo. The primary outcome was percentage of patients with CIDP relapse/withdrawal during 24-weeks of treatment determined by Inflammatory Neuropathy Cause and Treatment score. Secondary endpoints included grip strength and patient satisfaction.
Results: Both IgPro20 doses significantly reduced rate of CIDP relapse/withdrawal versus placebo. Grip strength remained stable with Hizentra V R , but deteriorated with placebo. Most subjects preferred SCIG over IVIG. Local reactions, reported in 24% of IgPro20-treated patients, were mild or moderate in intensity.
Conclusion: IgPro20 is efficacious and well-tolerated as maintenance treatment in CIDP. Introduction: Mutations in NFL gene cause autosomal dominant axonal CMT (CMT2E). There is no effective therapy for CMT2E, in part due to the paucity of preclinical models suitable for drug discovery. Objective: To develop a novel preclinical platform for CMT2E therapy development.
Methods:
We generated control and CMT2E patient-derived motor neurons and cultured them in suspension until they formed neurospheres.
Results: Immunostaining of CMT2E neurospheres revealed numerous areas of NFL accumulation in N98S CMT2E axons and co-accumulation of NFH, pNFH and NFM. Quantification of NFL signal intensity revealed that, despite the areas of NFL accumulation, CMT2E axons have a weaker overall NFL signal compared to control axons, suggesting that NFL accumulates in certain regions of CMT2E axons but is reduced in the areas with no accumulation.
Conclusion:
We identified a strong, disease-relevant, axonal phenotype in human CMT2E motor neurons with potential as a screening platform for drug discovery.
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THROMBOEMBOLIC RISK IN INFLAMMATORY NEUROMUSCULAR DISEASE PATIENTS ON LONG-TERM IVIg
Spillane J, Englezou C, S Sarri-Gonzales, A Rossor, Lunn MP, Manji J, Reilly MM, Carr AS. 1 MRC Centre for Neuromuscular Diseases, National Hospital for Neurology, Queen Square London Background: Observational data suggest IVIg increases risk of thromboembolic events(TEE). Traditional vascular risk factors influence individual risk but the pro-coagulant mechanism of IVIg is not understood.
Aims: To ascertain frequency of and risk factors for TEE in neuromuscular patients receiving regular IVIg.
Methods: Diagnosis, dose, frequency, vascular risk factors, pre and post-treatment IgG levels and plasma viscosity were recorded by retrospective casenote review.
Results: 112 patients received mean (S.D) dose:1.6 (1.2) g/kg/ month, range: 0.2-6.5 g/kg/month; mean (S.D.) interval:4.4 (3.0) weeks, range: 1-18 weeks for CIDP (58.9%), MMN (36.6%), sensory neuropathy/neuronopathy (3.7%) and myositis (0.9%).
Twelve TEEs occurred in 30 months; 6 MIs, 2 CVAs, and 1x TIA, DVT, PE, SVC obstruction. TEE incidence (95% C.I.)542.1 (18.6,67.1)/1000patient-years; ATE incidence5 32.1 (11.1,53.1)/1000patient-years; VTE510 (1.4,22.8)/1000 patient-years. In the event group all CVRF were higher but QRISK2 < 20% (low risk) in 25%.
Conclusions: TEE incidence was higher in this cohort than population-based rates (TEE54-4.5/1000; ATE5 3-3.5/1000 and VTE51/1000 patient-years). TEE was more common with elevated CVRF this does not impart all TEE risk associated with IVIg.
Objectives: To describe the Italian EAP experience with intrathecal Nusinersen in SMA1.
Methods: A national committee of experts in SMA, patient representatives and the Italian SMA Association ensured that the diffusion of treatment information and protocol, procedures and enrollment was shared and harmonized amongst families. Patients were assigned to 1 of 5 SMA referral centers based on travel distance and usual care. Motor, respiratory and nutritional data have been collected at each time point as well as family burden information.
Results: 127 genetically determined SMA1 patients were enrolled in the 5 Centers.
Conclusions: Data collection is ongoing. We expect to obtain longitudinal data on motor and respiratory function. Our data, although preliminary, may help in the design of the new natural history profile of patients with SMA1 in the Nusinersen EAP.
Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy due to the aberrant reactivation of DUX4 in de-repressed and/or contracted D4Z4 macrosatellite repeat units on chromosome 4q35. DUX4 is normally epigenetically silenced in somatic cells. Aberrantly reactivated DUX4 can turn on downstream targets that lead to muscle cell death. The Seattle/Rochester NIH-funded Wellstone Center followed 36 subjects with FSHD at the two sites over a one-year interval with strength assessment, functional outcome measures, lower-extremity MRIs, and MRI-informed muscle biopsies. RNA-Seq was performed to look at DUX4-target genes in the needle muscle biopsies. We compared T1 and STIR MRI changes to muscle histopathology and DUX4-induced downstream targets (PRAMEF1, TRIM43, KHDC1 and LEUTX). Interim findings from this study will be presented.
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A PHENOTYPIC PROFILE OF COGNITIVE FUNCTION IN CONGENITAL MYOTONIC DYSTROPHY (CDM)
M.M. Dixon, B. Otterud, K.N. Berggren, R. Crockett, H. Adams*, J. Bounsanga**, M. HUNG**, K. Bax***, C. Campbell****, B. Zielinski*****, N.E. JOHNSON. Department of Neurology, University of Utah; *Department of Neurology, University of Rochester; **Department of Orthopedics, University of Utah; ***Department of Education, University of Western Ontario; ****Department of Pediatrics, University of Western Ontario; *****Department of Pediatrics, University of Utah Introduction: CDM is associated with impaired cognitive function including intellectual disability, autism, and brain abnormalities.
Objective: Establish CDM cognitive phenotype inclusive of IQ, executive function (EF), adaptive behavior (AB), autism traits, brain morphology and function.
Methods: Participants (N551) with CDM (ages 0-13) were enrolled. IQ, EF, AB, and autism traits were measured. A subset (N513, ages 7-13) received brain MRI.
Results: IQ (x566.1, sd518.1), global executive dysfunction (teacher: x573, sd513.6), working memory impairment (parent: x568.6, sd510.7); low AB (x570, sd516.2); increased repetitive behavior (x516.4, sd514.7). Correlations: IQ and AB (r5.71, p5.001), communication AB and plan/organization (r5.76, p5. Introduction: Tongue abnormalities on brain MRI are underreported in patients with neuromuscular disorders (NMD).
Objectives: To review the tongue appearance on brain MRIs in various NMD and study the frequency of tongue abnormalities, the type of tongue abnormalities and whether abnormalities were reported on the original radiological or neurological interpretation.
Material and Methods: Chart and MRI review of patients with NMD.
Results: Abnormalities of the tongue were observed in 11/34 of the patients. In only one patient, the tongue was reported as abnormal in the radiology report. Tongue abnormalities were most frequent in patients with Pompe disease patients and those with ALS. Objectives: We conducted an RCT to assess efficacy and safety of bumetanide in treating an exercise induced attack of hand weakness in HypoPP.
Conclusion
Method: A randomised, double-blind, placebo-controlled phase II clinical trial with crossover design using abductor digiti minimi CMAP as an objective outcome measure.
Results: Nine participants completed both trial visits. There was no statistically significant difference in CMAP amplitude between the treatment groups at 1 hour (p50.27, primary outcome). Two participants recovered from the attack of weakness within 4 hours following Bumetanide intake; none recovered following placebo intake. There were no serious adverse events.
Conclusions: Bumetanide was safe but not effective to rescue a focal attack in an immobilised hand in the majority of patients. However, data supports further studies of this agent. Methods: 49 participants with CDM were recruited in to three age-based cohorts. Motor performance was assessed in the two oldest cohorts using the 4SC, RFF and 10MR. Each participant's Age Equivalent Receptive Communication was calculated using the Vineland Adaptive Behavior Scales-II.
Results: The 10MR time improved by 6.5% over 12 months. Participant's chronological age suggested/showed significant weak-modest negative correlations for 4SC (r5 2.39, p5.032) and 10MR (r5 2.39, p5.034). There was no significant correlation between participants age equivalent receptive communication and the 10MR, 4SC, or RFF.
Conclusion: Age equivalent receptive communication doesn't appear to correlate with performance/improvement on these measures. Perhaps suggesting performance on these measures is more closely associated with motor function/planning. Introduction: Children with congenital myotonic dystrophy (CDM) have dysarthria and dysphagia, which impacts quality of life with minimal objective data quantifying these issues.
Design: Forty children with CDM and 29 controls ages 0 to 13 years were enrolled. Lip and tongue strength was assessed using a lip force meter (LFM, in Newtons, N) and the Iowa Oral Performance Instrument (IOPI, in kilopascals, kPA). Speaking and eating were also qualitatively assessed.
Results: Mean LFM was 2.6 N (SD 2.7) in CDM and 17.8 N (7.6 SD) for controls (p<0.001). Mean IOPI data were 11.9 kPA (SD 7.9) in CDM and 41.8 kPa (SD 12.6) for controls (p<0.001). IOPI (ICC50.75) and LFM (ICC50.96) had good test-retest reliability. Ingestion of solids showed negative correlation with IOPI (20.463, p50.046) and LFM (20.612, p50.004) . Dysarthria was negatively correlated with IOPI (20.547, p50.012).
Conclusions: This work demonstrates reliability of instrumentation measuring orofacial strength in children and identifies correlations with features of dysphagia and dysarthria in CDM. Methods: Fifty CDM children aged 0-13 years and controls were enrolled. Parent/family functioning was correlated with child health-related quality of life (HRQOL) and disease factors.
Results: Family functioning is significantly affected in CDM patients compared to controls (P50.006). Better family functioning was associated with higher child HRQOL scores (q50.506, P50.005), less child fatigue (q5-0.407, P50.017), and higher child IQ (q50.445, P50.049).
Conclusion: CDM has an impact on family functioning, and various disease factors are associated with functioning. Better understanding these factors may help identify interventions to lessen the burden on families. Introduction: Previously we conducted patient interviews and a large cross-sectional study which identified 15 symptomatic themes of greatest importance to patients with FSHD.
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EVALUATION OF PAIN AND EMPLOYMENT STATUS IN THE PATIENT-REPORTED IMPACT OF SYMPTOMS
Objectives: To understand how FSHD disease burden relates to employment status and pain.
Methods: We determined the presence and relative importance (measured as impact scores ranging 0-4) of 15 symptomatic themes in a sample of 328 FSHD patients and examined their associations with pain and employment status.
Results: Employment status was associated with the presence of 12 symptomatic themes and impact scores of 8 themes. Employment status was most strongly associated with problems eating, problems with hands or fingers, and problems with physical health (p<0.0001). Participants with minimal or no pain reported a lower impact of 8 symptomatic themes with truncal weakness and fatigue having the strongest associations with pain (p<0.0001).
Conclusions: Employment and lower pain levels are associated with reduced disease burden in patients with FSHD.
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FEASIBILITY AND VALIDATION OF MODIFIED OCULOBULBAR FACIAL RESPIRATORY SCORE (mOBFRS) IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND SPORADIC INCLUSION BODY MYOSITIS (sIBM)
Authors: M. Wencel, N. Araujo, T. Mozaffar, N. Goyal (Irvine, CA)
ALS and sIBM are disorders that cause progressive facial, bulbar, and respiratory muscle weakness. Reliable patient reported outcome measures (PROs) are used in both disorders (ALSFRS-R and IBMFRS) to estimate the degree of facial, bulbar and respiratory involvement; however, we lack objective scales that quantitate deterioration in these functions.
The modified oculobulbar facial respiratory score (mOBFRS) is an objective test validated in myasthenia gravis. We will assess the use of the mOBFRS in ALS and sIBM patients at 3 time points. We will evaluate if changes in mOBFRS: 1) can be reliably measured on a serial basis; 2) parallel changes in other objective measures; 3) correlate with the sub-scores of the existing PROs; and 4) can be used as an outcome measure in clinical trials.
Since study initiation we have enrolled 115 ALS and 36 IBM subjects, demonstrating that conducting this test in clinic is feasible. Validation results are pending.
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RASCH ANALYSIS OF THE ADULT MYOPATHY ASSESSMENT TOOL SCALE IN SPINAL AND BULBAR MUSCULAR ATROPHY IN UK AND ITALIAN COHORTS
G Ramdharry*, L Zampredi*, G. Soraru**, G Querin**, S Fenu***, D. Pareyson***, P. Fratta* (London, UK*, Padua, Italy**, Milan, Italy***)
Introduction: The adult myopathy assessment tool (AMAT) is a 13-item functional measure. It has construct validity in 56 people with spinal and bulbar muscular atrophy (SBMA).
Objectives: This paper presents the first step of an analysis to identify where the AMAT could be modified to optimise the person-item fit and the performance of each item to the Rasch model.
Methods: Observations were collected from genetically confirmed SBMA cases in London, Milan and Padua. Data from each site were combined and cleaned for analysis using RUM2030 software.
Results: We analysed 122 observations. The scale was unidimensional and overall there was a good fit to the model, however, there was a lack of items for higher functioning patients, 11 items had disordered thresholds and 4 items displayed dependency.
Conclusions: We will modify the items to improve performance and reanalyse, but consideration must be given to items for higher functioning SBMA patients. Introduction: ACTIVE, a video-based outcome, assesses reaching abilities on a continuous scale in patients with spinal muscular atrophy (SMA). Long-term monitoring of function across a wide range of abilities is critical in the era of commercially-available treatments.
Objectives: Our objective was to understand the clinical meaningfulness of reaching ability measured by ACTIVE compared to self-or parent-reported quality of life measure in patients with SMA.
Methods: Sixty-one subjects with SMA completed two 70-second ACTIVE trials, the PROMIS upper extremity scale, and Brooke scale in one visit.
Results: ACTIVE was significantly correlated to PROMIS selfreport and parent-proxy (Spearman's rho, r50.88 and r50.78, respectively; P<0.01). Differences in ACTIVE were also significant between Brooke levels, with the exception of Brooke 3 and 4 due to sample size.
Conclusions: ACTIVE is an outcome measure that can both validly assess functional ability and track meaningful functional changes in patients with SMA.
CLINICAL MANAGEMENT
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EFFECT OF CNS CHANGES TO NEUROMUSCULAR DYSFUNCTION IS UNCLEAR
Laurie Gutmann, MD; Richard Shields, PT, PhD, FAPTA; Dan Thedens, PhD; Ian DeVolder, PhD; Janel Phetteplace, MS, CGC, Peg Nopoulos, MD (Iowa City, IA)
Objectives: Comparison of MRI findings in brain and muscle function of DM1 subjects.
Methods: 13 DM1 and 12 control subjects had brain MRI, cognitive battery, motor function evaluation, motor accuracy score (coherence) during weight bearing task, calf MRI: muscle volume, T2 relaxation and fat fraction. Analysis of covariance was used to control for age and sex effects. Brain structure measures and DTI were correlated with cognition, disease duration (DD), motor function, muscle MRI and coherence scores.
Results: 1) Reduced cerebral white matter volumes, regional decreased volume of thalamus and putamen 2) Diffuse reduction in white matter structural integrity (fractional anisotropy; FA):, directly correlated with IQ, DD, and MIRS 3) Controlling for DD, FA significantly correlated to MIRS, Muscle T2 and the coherence score.
Conclusions: Global cerebral FA and muscle structure/function correlations suggest CNS role in DM1 neuromuscular dysfunction. Introduction: Anecdotal evidence suggests a negative impact of mitochondrial disease on genitourinary function. However, this clinical observation has never been formally studied.
Objectives: To investigate the effects of mitochondrial disease on bladder and sexual function.
Methods: We plan to recruit 50 genetically confirmed adults with mitochondrial disease, alongside age and gender matched controls. A validated questionnaire will be utilised to characterise bladder and sexual dysfunction.
Results: 42 patients and 14 controls have been recruited. Preliminary data analysis suggests women with mitochondrial disease experience more bladder symptoms, particularly overactive bladder symptoms, with a greater impact on quality of life, than controls. There is also a trend towards sexual dysfunction.
Conclusions: These preliminary data suggest that mitochondrial diseases affect bladder and sexual function. Patients should therefore be actively screened for these symptoms in clinic to ensure optimal management. Future work will focus on unravelling the pathomechanisms underpinning this bladder and sexual dysfunction. Introduction: ALS8 is a rare form of familial amyotrophic lateral sclerosis (FALS), caused by mutation in vesicle associated membrane protein-B (VAPB) which has not been reported in USA.
Case Report: A 37 year-old Caucasian man presented with a 5-year history of progressive leg weakness and hand tremor without bulbar symptoms. There was a strong family history of ALS. Electrodiagnostic study revealed diffuse lower motor neuron degeneration. Genetic studies for SOD1, FUS, TARDBP, ANG, OPTH, and C9ORF72 were negative. A missense-mutation (p.P56S) was identified in the VAPB gene. Over next 33 months, patient became bedridden and developed significant respiratory insufficiency.
Discussion: FALS8 can present as typical/atypical ALS or spinal muscular atrophy. P56S is a dominant missense mutation previously described in families of Portuguese-Brazilian, German and Chinese origin. P56S-mutation results in VAPB aggregation, resulting in increased stress of endoplasmic reticulum. Further elucidation of mechanism leading to an ALS-phenotype is needed. Introduction: People with neuromuscular diseases have been shown to be less active with increased occurrence of cardiopulmonary de-conditioning. This has implications for general health and risk of co-morbidities.
Objectives: Compare cardiopulmonary exercise testing (CPET) variables for people with CMT and IBM compared to predicted values for age, sex and weight.
Methods: Participants underwent CPET testing using a bicycle ergometer. Variables measured were maximum heart rate (HRmax), VO2peak, anaerobic threshold and ventilatory efficiency (V E /VCO 2 ).
Results: We recruited 22 people with CMT and 18 people with IBM. CPET variables were significantly lower than predicted values for both conditions. CMT subjects had VO2 peak values 77% of predicted, and in IBM it was 57%. IBM subjects had significantly lower VO2peak and HRmax than people with CMT.
Conclusions: Both disease groups show evidence of cardiopulmonary de-conditioning, particularly in IBM. Aerobic exercise training could be an important intervention to improve general health and co-morbidity risk. Background: Primary mitochondrial disease (PMD) is a heterogenous group of disorders characterized by impaired energy production as a result of genetic mutations. Primary mitochondrial myopathy (PMM) describes a subset of PMD and can manifest as muscle weakness, muscle atrophy, and exercise intolerance.
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Purpose: To understand healthcare utilization in patients diagnosed with PMD.
Methods: This study was a retrospective claims analysis using Truven Health Analytics Marketscan Commercial and Milliman's proprietary commercial datasets in patients with an ICD9/ 10 for PMD. Claims are reported on an allowed cost Per Member Per Month (PMPM) basis.
Results: 3,825 patients between the ages of 0 and 15 (pediatric) and 4,358 patients between the ages of 16 and 65 (non-pediatric) were identified. Total allowed PMPM for pediatric patients was $4829 and for non-pediatrics was $3100. The greatest resource utilization came from prescription medications, physician visits, home health and therapy, with greatest cost drivers from inpatient, surgery, prescription medications, and home health.
Conclusions: This retrospective claims study highlights the significant differences in the costs of medical care for PMD patients Case report: A 20-year-old Caucasian man who was born fullterm, hypotonic at birth, presented with slightly delayed motor milestones, cognitive impairment, prominent marfanoid features (including aortic root dilatation), as well as a mild congenital myopathy without cardiomyopathy. Neuromuscular examination revealed hypotonia with mild axial and appendicular weakness in both proximal and distal muscle groups. Testing for a panel of genes causing congenital muscle disease revealed a single heterozygous variant in the LMNA gene (c.1634 G>A; p.Arg545His).
Conclusions: Laminopathies should be considered in sporadic patients with marfanoid features associated with a mild congenital myopathy phenotype. c.1634 G>A variant can be considered a "mutation" in genetic variant databases. Our patient again shows the complexity of overlapping phenotypes in laminopathies. Introduction: Charcot-Marie-Tooth (CMT) is the most common inherited neuropathy. However, the impact of pregnancy on CMT symptoms and the implications of the neuropathy during pregnancy, delivery and immediately post-partum, have not been fully investigated.
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MONITORING PREGNANCY IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE AND RELATED HERIDITARY NEUROPHATIES: RESULTS OF SURVEY
Objectives: To assess the impact of pregnancy on CMT symptoms and to investigate whether the neuropathy has any implications during pregnancy and delivery or with post-partum care
Methods: We designed a retrospective questionnaire composed of four sections: before, during and after pregnancy; and delivery). 29 questions addressed impairment, falls, pain, fatigue and respiratory complications, delivery type, complications, anaesthetic details and difficulties looking after the newborn.
Results: Preliminary data confirmed deterioration of CMT symptoms in 36% of pregnancies with resolution in 47%. 59% of women had natural deliveries, 13% were assisted and 28% had caesarean sections, comparable with the general UK population. There were no anaesthetic complications.
Conclusion:
Data from this survey provides valuable information on current practice and should inform future guidelines/ standards of care in CMT.
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MUSCLE & NERVE September 2017 25   THE  MRC  CENTRE  FOR  NEUROMUSCULAR  DISEASES OBSERVATIONAL COHORTS: A TOOL TO  TRANSLATE  DISCOVERY  SCIENCE  INTO  TREATMENTS FOR Introduction: Observational cohort studies, including natural history studies, aligned to stored biomaterials, are crucial to deliver translational medicine. They constitute the basis for proof of principle studies of potential therapies and clinical trials.
Objectives: To provide updated figures about the MRC Centre for neuromuscular diseases observational cohorts and increased recruitment numbers over time.
Methods: Ongoing deep phenotyping effort with protocolised data collection that promotes the characterisation of patients at the clinical, genetic, histopathological, electrophysiological, serologic and imaging level. 
Conclusions:
The core diagnostic and phenotypic data collected through observational cohort studies, linked to stored biomaterials, are crucial to deliver translational medicine. They are the basis for proof of principle studies of potential therapies and clinical trials. Improved understanding therefore has significant potential to inform therapy and outcomes for those affected.
Objectives: To investigate the frequency of VD in MD patients seen by a specialist neuromuscular Physiotherapist in a national MD clinic.
Methods: Patient reported symptoms relating to dizziness/imbalance and neuro-otological findings were recorded and analysed.
Results: 42 patients with dizziness/imbalance were reviewed; VD was detected in 69% of those referred for neuro-otological assessment.
Conclusions: A neuro-otological diagnosis and customised vestibular rehabilitation should be considered in all MD patients reporting dizziness/imbalance. 
CLINICAL TRIALS
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A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL ON THE CLINICAL EFFICACY OF NIV AND MODAFINIL ON EXCESSIVE DAYTIME SLEEPINESS (EDS) IN MYO-
Introduction:
There is yet no consensus on the treatment of EDS in DM1.
Objectives: To describe a multicenter, RCT ongoing trial on the clinical efficacy of NIV and modafinil to treat EDS in DM1.
Methods: 80 DM1 patients with objective EDS will be subjected to respiratory and sleep studies and randomized to modafinil or placebo either directly or while on NIV where indicated and if EDS persists despite NIV and the correct ventilator profile.
Results: 10/80 patients have been screened and 4 having EDS alone will be randomized to modafinil or placebo.
Conclusions:
We expect that Modafinil will improve central EDS in DM1, with or without NIV and will possibily improve NIV compliance. The study will also provide data on the effects of NIV on respiratory function and quality of life.
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OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
F. Cohen (Trevose, PA)
Introduction: Dichlorphenamide is a carbonic anhydrase inhibitor FDA-approved for treatment of primary periodic paralyses.
Objectives: Evaluate single-and multiple-dose pharmacokinetics, safety.
Methods: Dichlorphenamide was administered to 6 cohorts (n56 each) of healthy male and female volunteers. Cohorts A-E received once-daily doses of 25-400 mg 3 days, then 50-800 mg/day in twice-daily doses (10). Cohort F (safety analysis only) received 28 titrated doses of 100-800 mg/day in twice-daily doses.
Results: Twenty-five of 36 enrolled subjects completed the study. C max range was 1-3 hours; T 1/2 range was 32-68 hours. Mean AUCs and C max increased dose-proportionately after multiple doses. Incidence and severity of AEs were dose-related.
Ten of 11 discontinuations were AE-related (Cohorts D, E, F). Hypokalemia contributed in 5 of 6 discontinuations (Cohort F).
Conclusion: Dichlorphenamide demonstrated dose-proportionate pharmacokinetics and was well tolerated in labeled dosing; higher doses were associated with increased severity, incidence of AEs. Background: Dermatomyositis (DM) is one of the idiopathic inflammatory myopathies and the early symptoms include characteristic skin manifestations accompanying or preceding progressive muscle weakness.
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EVALUATING EFFICACY AND SAFETY OF A 10% INTRAVENOUS IMMUNOGLOBULIN SOLUTION IN PATIENTS WITH DERMATOMYOSITIS (PRODERM STUDY) -DESIGN OF A PHASE III STUDY
Purpose: The ProDERM study aims to investigate the efficacy, safety and tolerability of Octagam 10% IGIV (Intravenous Immunoglobulin) preparation in patients with active dermatomyositis.
Methods: The ProDERM study is planned as a prospective, parallel group, double-blind, randomized, placebo-controlled, multicentre, phase III global study. In total, 94 adult patients with definite or probable DM will be enrolled and randomized 1:1 to either high dose (2g/kg) IGIV or placebo treatment every 4 weeks.
Results: Primary objective is to provide efficacy data on the effect of 2.0 g/kg IGIV every 4 weeks compared to placebo in active DM based on percentage of responders at week 16. Secondary objectives are to evaluate long-term benefits (40 weeks) and tolerability of IGIV 10% treatment in DM patients. Background: IGIV is a treatment choice in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) because of its rapid onset of action and its relatively safe long-term adverse event profile.
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Purpose: Confirm published clinical results obtained with the 1.0 g/kg IVIG standard dose and evaluate other maintenance doses for personalized treatment options.
Methods: A prospective, double blind, randomized, parallel group, multicentre phase III study in 44 centres. 140 adult patients with definite or probable CIDP according to the EFNS/ PNS Criteria will be enrolled and randomized 1:2:1 to receive either 0.5 g/kg or 1.0 g/kg or 2.0 g/kg IVIG (Panzyga V R ) for seven maintenance infusions at 3-week intervals during the Dose-evaluation Phase. The starting loading dose will be 2.0 g/kg IVIG for all patients.
Results: The primary objective is to measure efficacy (INCAT criteria) as percentage of responders to 1.0g/kg IVIG in CIDP. The secondary outcome is to determine efficacy of 0.5g/kg and 2.0g/kg IVIG as additional maintenance options. RA101495 is a subcutaneously-administered macrocyclic peptide which binds C5 and inhibits its cleavage into C5a and C5b, preventing production of the membrane attack complex.
Objectives: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RA101495 in healthy volunteers.
Methods: Subjects were randomized to receive once daily subcutaneous injections of 0.2 mg/kg RA101495 (n54), or placebo (n52), for 7 days in a Phase 1 unit.
Results: Drug levels were consistent with predictions from insilico modeling. Exposures increased steadily over 7 days, consistent with a terminal half-life of approximately 7 days. Mean percent inhibition of complement activity was 95% from 3 hours after first dose through day 7. No safety concerns were identified. Three RA101495-treated subjects experienced transient mild injection site erythema.
Conclusions: These data support further study of RA101495 in an upcoming MG Phase 2 study. Objectives: The aim of the project will be to determine whether physical exercise is safe and beneficial in patients with ALS.
Methods: We planned a randomized, single blind, controlled study based on the use of endurance training in ALS patients. Subjects were blindly randomized into two treatment groups, Usual Care Group (respiratory, proprioceptive and stretching exercises) or Endurance Group (the same treatment plus cycle ergometer training) and evaluated at baseline (T0) and after treatment (T1). The full assessment included several outcome measures: 6-MWT, ALS Functional Rating Scale-Revised (ALSFR-R), Vital Capacity (VC), Oxygen consumption, Upper and lower limb strength by Medical Research Council scale (MRC) Results: A total of 100 subjects were recruited. We found a significant improvement in both groups in the 6-MWT (p=0.013) but more in Endurance Group (p=0.01). No differences in ALSFRS-R score and VC.
Conclusions:
The most important result of the study is that a tightly controlled rehabilitation protocol is effective and well tolerated in ALS patients. Case Report: A 27-year-old woman with Arnold-Chiari malformation, hydrocephalus, high-arched palate, bilateral hip dysplasia, and severe scoliosis presented for evaluation of episodic muscle stiffness and weakness since adolescence.
PATHOGENESIS
Results: Electrodiagnostic studies revealed myopathy and myotonia. Muscle histopathology showed marked fiber size variability, type I fiber predominance, minimal scattered necrosis and regeneration, and lobulated type I fibers. Gene testing revealed a novel de novo heterozygous c.2386C>G, p.Leu796Val missense mutation in SCN4A.
Conclusions: This is the first report of a dominant, heterozygous mutation in SCN4A causing a complex phenotype of congenital myopathy, myotonia, congenital anomalies and unique muscle pathology findings, adding to the ever expanding phenotype of SCN4A mutations.
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GENETIC MODIFIERS OF SEVERITY IN COLLAGEN VI RELATED MUSCULAR DYSTROPHY
A.D. Loret, D.M. Dunn, R.J. Butterfield, and R.B.
Weiss (Utah)
Introduction: Collagen VI related muscular dystrophies (COL6-RD) display phenotypic heterogeneity that includes mild Bethlem myopathy (BM), intermediate, and severe Ullrich congenital muscular dystrophy (UCMD) phenotypes. Variation in phenotypic severity is not fully explained by primary mutation, suggesting the presence of genetic modifiers.
Objectives: We sought to determine whether LTBP4, a regulator of TGF-b signaling, serves as a genetic modifier of severity in COL6-RD.
Methods: Genotyping of the four single nucleotide polymorphisms (SNPs) that define the milder IAAM haplotype of LTBP4 was performed in a cohort of comprehensively phenotyped COL6-RD patients.
Results: LTBP4 haplotype was determined in 122 patients with COL6-RD and associated with clinical severity outcomes using linear regression analyses.
Conclusions: These studies provide critical insights into the phenotypic heterogeneity seen in patients with COL6-RD, identify targets for the development of therapies, and provide an important model for future studies of the molecular pathogenesis. Introduction: Despite our understanding of the molecular pathways underlying muscle atrophy, no specific cure has yet been produced. We have identified ncRNAs that are specifically expressed in the earliest muscle precursor cells. Some of the ncRNAs, chiefly the miR-322/503 cluster, may mediate muscle atrophy in a range of diseases.
Objectives and Methods:
The objective is to determine the phenotypes and mechanisms of skeletal muscle-specific overexpression of miR-322/503.
Results: A LacZ reporter knocked into the miR-322/503 locus demonstrated specific expression in striated muscles. Ectopic expression of miR-322/503 in skeletal muscles led to significantly reduced muscle and body masses. Surveying the transcriptome of miR-322/503 Tg muscles demonstrated inhibitions on components of the IGF/AKT/mTOR pathway. miR-322/503 directly targets eIF4E and eIF4G1, in addition to the established target, IGF1R.
Conclusion: miR-322/503 plays a pivotal role in regulating skeletal muscle homeostasis, likely through targeting multiple components that converge on translation initiation. Objective: To evaluate in-vivo reflectance confocal microscopy (RCM) of Meissner's corpuscles (MC) and conventional neuropathy measures as peripheral nerve (PNS) markers in FA.
Methods: Sixteen patients with FA and 16 controls underwent RCM of MC density and morphology, skin biopsies for epidermal nerve fiber density (ENFD), nerve conduction studies (NCS), and QST (monofilament. vibration, and cooling thresholds). The Friedreich's Ataxia Rating Scale (FARS) was assessed in FA patients.
Results: Differences in MC density and diameter, NCS, and QST measurements were detected in patients with FA relative to controls. FARS correlated with MC density, QST, and ENFD. Sensory nerve conduction responses were obtainable in only 13% of FA patients, while MC densities were measureable in 87% of patients.
Conclusions: RCM of MC density and morphology and conventional neuropathy measures provide complementary objective markers for PNS involvement in FA.
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A NEW SYT2 MUTATION CAUSING PRESYNAPTIC NEUROMUSCULAR JUNCTION DYSFUNCTION AND DISTAL MOTOR NEUROPATHY (LEMS-CMT)
Montes-Chinea, NI*, Coutts, M*, Vidal C*, Courel, S**, Rebelo A**, Abreu L**, Zuchner S**, Saporta, MA* , **. (Department of Neurology, University of Miami, Miami, USA*, Department of Human Genetics, University of Miami, Miami, USA**) Introduction: Autosomal dominant pathogenic mutations in Synaptotagmin-2 (SYT2), affecting its C2B-domain, have been linked to presynaptic neuromuscular junction (NMJ) dysfunction and motor neuropathy in two families.
Case report: 50-year-old woman with normal developmental milestones presented with pes cavus, hammertoes since 8-yearsold, progressive bilateral distal leg and hand weakness, falls and cramping. Her maternal grandfather, two maternal uncles, mother and sister reported similar symptoms. Examination revealed significant distal lower extremity weakness and absent ankle deep tendon reflexes. EMG/NCS revealed normal sensory responses, globally reduced motor amplitudes with >100% increment after brief isometric contraction. Ulnar nerve slow (3Hz) repetitive nerve stimulation showed 40% amplitude response decrement with >100% increase after one-minute of sustained contraction. Voltage-gated calcium-channel antibodies and chest-CT were normal. Sanger sequencing revealed an Ile371Lys mutation in the C2B-domain of SYT2.
Conclusion: SYT2-related neuropathy should be suspected in patients with a presynaptic NMJ-dysfunction, predominantly motor neuropathy, and positive family history. Introduction: Diagnosing adult mitochondrial diseases can be challenging due to their genetic heterogeneity.
Objectives: To apply next-generation sequencing (NGS) in adults with genetically unconfirmed mitochondrial disease.
Methods:
We utilised targeted and whole exome sequencing in adults with clinical and pathological and/or biochemical evidence of underlying primary mitochondrial dysfunction. Prior whole mtDNA and mitochondrial nuclear maintenance gene sequence analysis was normal.
Results: 50 probands have been recruited to date. Causative gene mutations have been identified in 14% (7/50) of cases. Mutations in the myopathy-associated genes GNE and MYH7 were detected in two pedigrees; the latter co-existing with a USH2A gene mutation, thus mimicking mitochondrial disease.
Introduction: Hypokalaemic periodic paralysis (hypoPP) is characterised by episodes of flaccid skeletal muscle paralysis accompanied by low serum potassium.
Objective: identify the cause of hypoPP in a young boy lacking mutation in known periodic paralysis genes (CACNA1S, SCN4A, KCNJ2).
Methods: Targeted exome sequencing. Two Electrode Voltage Clamp and xenopus oocyte system.
Results: He experienced mild learning difficulties and at 4 months had a GTCS. Age 2 he woke with tetraparesis lasting hours. Recurrent episodes, averaging 5 to 10/month. CK 587 -775IU/L. Ictal serum potassium (2.4). Muscle biopsy myopathic, MRI head/EEG unremarkable. Symptoms responded to daily potassium but worsened with acetazolamide. A novel variant in ATP1A2 coding for the sodium-potassium ATPase was idenitifed. Functional analysis demonstrates an aberrant inward leak current exaggerated at low pH.
Conclusions: Known hypoPP mutations alter sarcolemmal excitability by introducing an inward leak current. Functional analysis demonstrates the same pathomechanism, suggesting ATP1A2 is a new cause of hypoPP. Introduction: Excitation-contraction coupling (ECC) undergoes age-related changes in animal models that potentially link with Sarcopenia.
Objectives: To investigate expression of ECC proteins in human muscle
Methods: RNA sequencing and phenotype data from the GeneTissue-Expression-Project were used (age 21-70). 361 gastrocnemius samples were clustered according to normalised expression of key ECC genes using K means (K52). Significant cluster-phenotype associations were investigated using a linear regression model.
Results: Cluster 1 samples had more deaths secondary to heart attack or pulmonary embolism (p50.0002), increased median ischaemic time (602 vs 394 hours) and relatively reduced expression of proteins related to maintenance of membrane potential. Cluster 2 had more ventilated patients (60% Vs 34%), more deaths secondary to stroke or intracerebral haemorrhage (p50.0004) and relatively reduced expression of proteins related to calcium homeostasis. There was no significant difference in mean age.
Conclusions:
The data suggest that immobility and ischaemia may be important modulators of ECC protein expression. LGMD2A is caused by mutations in calpain 3 (CAPN3), a calcium dependent protease.
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LGMD2A is unique because it is characterized by profound loss of muscle mass without significant degeneration and regeneration.
LGMD2A does not involve impaired membrane integrity, like the widely studied dystrophinopathies. Our prior studies revealed that CAPN3 serves an undefined role in maintaining the integrity of the muscle triad. These changes correlated with blunted calcium calmodulin kinase beta signaling (CaMKIIb) and a blunted transcriptional response to the stimulus of muscle loading. We further mapped these pathways to identify signals that emanate from CaMKIIb to affect adaptive gene transcription that mediates remodeling. Thus, our studies have defined a novel pathway involved in muscle remodeling and have demonstrated that defects in this pathway underlie a muscular dystrophy. This pathogenic pathway may extend to a larger group of diseases which are linked to proteins involved in triad maintenance or regulation.
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NONCLINICAL DEVELOPMENT OF CELL-PENETRATING PEPTIDES CONJUGATED PHOSPHOR-ODIAMIDATE MORPHOLINO OLIGOMERS (PPMO) FOR DUCHENNE MUSCULAR DYSTROPHY (DMD)
